High serum adenosine deaminase activity and its correlation with lymphocyte subsets in myasthenia gravis

S Chiba1, H Matsumoto, Y Motoi

  • 1Department of Rehabilitation and Neurology, Sapporo Medical College, Japan.

Insights

Serum adenosine deaminase (ADA) activity is elevated in myasthenia gravis (MG) patients, correlating with disease severity and anti-acetylcholine receptor antibodies. This suggests ADA may impact MG pathophysiology by altering lymphocyte function.

Area of Science:

  • Immunology
  • Neurology
  • Biochemistry

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
  • Adenosine deaminase (ADA) is an enzyme involved in purine metabolism and immune cell function.

Purpose of the Study:

  • To investigate serum ADA activity and peripheral lymphocyte subsets in MG patients.
  • To explore the relationship between ADA activity, disease severity, and immunological markers in MG.

Main Methods:

  • Simultaneous measurement of serum ADA activity and peripheral lymphocyte subsets in MG patients (n=30), normal controls (n=150), and multiple sclerosis patients (n=12).
  • Correlation analysis between ADA activity, MG clinical grades (Osserman's classification), and anti-acetylcholine receptor antibody status.

Main Results:

  • Serum ADA activity was significantly higher in MG patients compared to controls (P < 0.05).
  • Elevated ADA activity correlated with generalized MG, higher clinical grades (IIB vs. I), severe disease, and positive anti-acetylcholine receptor antibodies (P < 0.05).
  • A positive correlation was observed between ADA activity and the proportion of OK Ia1+ cells (P < 0.05), although other lymphocyte subsets showed no specific trend related to MG severity.

Conclusions:

  • Elevated serum ADA activity is a characteristic finding in myasthenia gravis.
  • High ADA activity may contribute to MG pathophysiology by influencing peripheral lymphocyte function and potentially impacting disease severity.

Related Concept Videos

Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...